Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Active Not Recruiting Phase 2 Trials for Paclitaxel (DB01229)

Also known as: Resectable Pancreatic Ductal Adenocarcinoma

IndicationStatusPhase
DBCOND0115304 (Resectable Pancreatic Ductal Adenocarcinoma (PDAC))Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04481204
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc StudyTreatment